Xeris Biopharma Holdings Q2 EPS $(0.18) Misses $0.00 Estimate, Sales $92.100M Beat $90.225M Estimate
Xeris Biopharma Holdings (NASDAQ:XERS) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $0.00 by Infinity percent. This is a 1700 percent decrease over losses of $(0.01) per
Xeris lost more money per share than experts thought it would, even though their sales came in a bit higher than expected. When a company loses more money than people predicted, it's a sign to watch if they're getting closer to making a profit or if problems are getting worse.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.